IE44458B1 - Compositions for treating hypercholesterolemia - Google Patents

Compositions for treating hypercholesterolemia

Info

Publication number
IE44458B1
IE44458B1 IE213/77A IE21377A IE44458B1 IE 44458 B1 IE44458 B1 IE 44458B1 IE 213/77 A IE213/77 A IE 213/77A IE 21377 A IE21377 A IE 21377A IE 44458 B1 IE44458 B1 IE 44458B1
Authority
IE
Ireland
Prior art keywords
vitamin
composition according
fatty acid
polyester
fat
Prior art date
Application number
IE213/77A
Other versions
IE44458L (en
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/657,528 external-priority patent/US4005195A/en
Priority claimed from US05/657,529 external-priority patent/US4005196A/en
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of IE44458L publication Critical patent/IE44458L/en
Publication of IE44458B1 publication Critical patent/IE44458B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23DEDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013Other fatty acid esters, e.g. phosphatides
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25Synthetic polymers, e.g. vinylic or acrylic polymers
    • A23L33/26Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Edible Oils And Fats (AREA)
  • General Preparation And Processing Of Foods (AREA)

Description

The present invention relates to certain edible, but non-absarbable and non-digestibla, liquid polyesters which can be used as low calorie fat substitutes in foods and as pharmaceutical compositions.
. The polyesters herein interfere with ths body's absorption of cholesterol and thereby provide c siaans fcr treating hypercholesterolemia. The polyesters can undesirably interfere with the body's, source of fatsoluble vitamins,, but in a preferred execution this . problem is overcome by fortification with vitamins.
It has been determined that the liquid polyesters herein can also cause an undesired anal leakage effect. Sy the present invention, certain agents are added. to the polyester compositions to avoid this undesired effect.
Preferred compositions for treating hypercholesterolemia and/or hyperlipidemia comprising the polyesters and antianal leakage agent are provided. Highly preferred compositions for treating hypercholesterolemia and/or hyperlipidemia comprising the polyesters, an anti-anal leakage agent, and one or more fat-soluble vitamins are provided.
High blood cholesterol (hypercholesterolemia) is. recognized as being a risk factor in cardiovascular disease which comprises a major health care, problem today. Epidemiological studies have demonstrated that, - 3 with few exceptions, populations consuming large quantities of saturated fat and cholesterol have a relatively high concentration of serum cholesterol and a high mortality rate from coronary heart disease. While it is recognized that other factors can also contribute to the development of cardiovascular disease, there appears to be a causal relationship between the concentration of serum cholesterol, in which hypercholesterolemia results in the accumulation of undesirable amounts of cholesterol in various parts of the circulatory system (atherosclerosis) or in soft tissues (xanthomatosis), and coronary disease and coronary mortality rates.
A variety of dietary and drug regimens have been suggested for alleviating or preventing hypercholesterolemia.
By providing a fat substitute which is nonabsorbable and non-digestible, the total content of cholesterol in the body can be lowered. Mineral oil is a well-known laxative and has been suggested for use as a fat substitute and as a kind of intestinal solvent to dissolve cholesterol and cause its removal in body wastes. However, mineral oil has never been accepted for these uses. Moreover, mineral oil is partially absorbed by the body and undesirably deposits in the liver.
In the present invention, liquid, non-absorbable, non-digestible polyesters of sugars (or sugar alcohols) are used as fat substitutes in foods and, conveniently, in unit dose forms as therapeutic compositions. The polyesters herein are fat-like in their physical properties and are excellent fat substitutes for use in low calorie foods and diets. Moreover, the polyesters herein efficiently inhibit absorption of cholesterol by the body and in contrast with mineral oil, are not 4458 - 4 absorbed and/or deposited in the liver during usage in a treatment/prevention regimen with persons having or likely to develop hypercholesterolemia.
The anal leakage effect of the liquid polyesters of the type disclosed herein can be overcome by adding an anti-anal leakage agent of the type disclosed hereinafter to the liquid polyesters, or to foods containing same.
U.S. Patent 3,600,186 (1971) to Mattson and Volpenhein discloses low calorie food compositions containing polyol polyesters of the general type employed herein, and their use in combination with hardstocks which are fatty acid sources. The anti-anal leakage effect of fatty acids is not noted.
Patent Specification No. 40307 discloses and claims sugar polyesters of the general type employed herein for the treatment and/or prevention of hypercholesterolemia. A variety of optional carriers are mentioned, including the fatty acid, stearic acid. The anti-anal leakage effect of stearic acid is not mentioned.
U.S. Patent 1,656,474 (1928) to Dubin discloses edible fat compositions consisting of ethyl and glycerol esters of odd chain fatty acids in combination with fat-soluble vitamins, Mattson and Molen, The Journal of Nutrition Vol, 102, No. 9, Sept. 1972, at pages 1171-1175, report on the lack of absorbability of sugar polyesters of the general type employed herein in rats.
Fallet, Glueck, Mattson and Lutmer, Clinical Research XXIII No. 3, page 319A (1975) report the lowering of both serum cholesterol and vitamin A and E levels in subjects receiving sugar polyesters of the present type.
U.S. Patent 2,962,419 (I960) to Minich relates - 5 to neopentyl fatty esters and their use as fat substitutes.
U.S. Patent 3,160,565 (1964) to Η. E. Duell relates to sugar mono-, di- and tri-esters and their use as carriers for various orally-administered medicinals.
U.S. Patent 3,849,554 (1974) to Winitz discloses means for reducing blood serum cholesterol by ingesting diets comprising a fatty acid source, said diets being low in sucrose.
U.S. Patent 2,893,990 (1959) to Haas, et al., discloses fatty acid mono- and di-esters of sucrose which aid in the absorption of fat from the digestive tract.
U.S. Patent 3,158,490 (1964) to Baur and Lutton discloses non-cloudy salad oils containing esters of di-saccharides in which there are not more than five un-esterified hydroxy groups. See also U.S. Patents 3,059,009 (1962) and 3,059,010 (1962) to Schmid and Baur.
U.S. Patent 2,997,492 (1961) to Martin is directed to a method of making partial fatty acid esters of hexitols. U.S. Patent 2,997,491 (1961) to Huber is directed to the synthesis of partial fatty esters of inositol. The general methods of synthesis disclosed in these patents can be used to prepare the liquid polyesters herein. Preferred methods of synthesis are fully disclosed hereinafter.
In addition to the foregoing, there are other patents directed to the use of fat-soluble vitamins in a variety of naturally-occurring oils not contemplated by the present invention. See, for example, U.S.
Patent 2,685,517, issued August 3, 1954, to Nutrition Products, Inc. } 4 4 5 8 - 6 Administration of anti-hypercholesterolemic amounts of a composition comprising a liquid polyester of the type described herein to an animal (especially humans) afflicted with or susceptible to hypercholesterolemia is an effective means of controlling the body's cholesterol level. Unfortunately, administration of cholesterol-controlling amounts of the liquid polyesters can result in an undesired laxative effect, namely, leakage of the liquid polyester through the anal sphincter. By combining the polyester compositions with an anti-laxative agent, especially an edible source of a C^2, or higher, saturated fatty acid, which provides such fatty acids in the gut, this undesired laxative effect is prevented. (By anti-anal leakage agent, or AAL agent, herein is meant those materials which prevent frank leakage of the liquid polyesters. The natural stool-softening effect of the polyesters is not substantially affected, nor is it a problem).
The present invention provides an antihypercholesterolemia and/or anti-hyperlipidemia composition comprising: (a) an edible, non-absorbable, non-digestible polyol fatty acid polyester which is liquid (as hereinafter defined) and whioh has at least 4 fatty acid ester groups, wherein the polyol is selected from the group consisting of sugars and sugar alcohols, containing from 4 to 8 hydroxyl groups and wherein each fatty acid group has from about 8 to about 22 carbon atoms; and (b) sufficient anti-anal leakage agent to prevent leakage of said liquid polyester through the anal sphincter, the anti-anal leakage agent being selected from edible, digestible sources of C^2 and higher saturated fatty acids (other than the acid per se); edible non-absorbable, non-digestible solid polyol fatty acid polyesters having at least 4 fatty acid ester groups, - 7 wherein the polyol is selected from the group consisting of sugars and sugar alcohols containing from 4 to 8 hydroxyl groups and wherein each fatty acid group has from about 8 to about 22 carbon atoms; and edible, non-digestible esters of alpha-branched chain cioC·^ fatty acids, and mixtures thereof.
Preferred executions of the invention herein further comprise sufficient fat-soluble vitamins selected from the groups consisting of vitamin A, vitamin D, vitamin E and vitamin K, or mixtures thereof, to prevent abnormally low tissue levels of any said fatsoluble vitamins in animals ingesting said compositions.
The present invention also encompasses nonlaxative pharmaceutical compositions in effective unit dosage amounts for inhibiting the absorption of cholesterol, said compositions comprising from 0.1 gram to 5 grams, preferably from 1 gram to 5 grams of the liquid polyesters herein and sufficient AAL agent, especially an edible source of a C12, or higher, saturated fatty acid to prevent anal leakage in humans ingesting said compositions. Preferably, the compositions also comprise the fat-soluble vitamins.
The polyester materials herein are non-absorbable and non-digestible fat-like materials and are suitable for use as fat substitutes in low calorie fat-containing food compositions. Accordingly, the present invention also encompasses low calorie fat-containing food compositions comprising non-fat ingredients and fat ingredients wherein from about 10% to about 100% of the total fat ingredients comprise the liquid, non-absorbable, non-digestible polyesters of the type disclosed hereinafter, said compositions also containing an effective amount of an AAL agent, especially an edible source of a C12, or higher, saturated fatty acid which prevents an undesirable anal leakage effect. Preferred 4 4 5 8 - 8 executions of the low calorie fat-containing food compositions herein further comprise sufficient fatsoluble vitamins, or mixtures thereof, over and above that naturally present in said food compositions, to prevent abnormally low levels of any said fat-soluble vitamins in humans ingesting said compositions.
The present invention also encompasses methods for inhibiting the absorption of cholesterol without causing an anal leakage effect, comprising systemically (generally, orally) administering to animals susceptible to or afflicted with hypercholesterolemia successive therapeutically effective doses of the composition of the foregoing type.
The present invention also emcompasses methods for inhibiting the absorption of cholesterol without decreasing the tissues' supply of fat-soluble vitamins or causing an anal leakage effect comprising administering (generally, orally) to non-human animals susceptible to or afflicted with hypercholesterolemia successive therapeutically effective doses of the compositions of the foregoing type fortified with fat-soluble vitamins.
It is to be understood that the edible, nonabsorbable, non-digestible polyester materials herein are liquids at body temperature, i.e., having a melting point of ca. 37°C or below. (Edible, non-absorbable, non-digestible polyester materials that are solid at body temperature do not exhibit the undesirable anal leakage effects noted with the liquid polyesters. Indeed, such solid polyesters can be used as ene type of AAL agent herein). In general, the liquid polyesters are those which are made from unsaturated fatty acids, whereas the solid polyesters are substantially saturated.
The consumption of diets containing sucrose polyesters (SPE) has been shown to result in the desirable decrease in absorption of dietary cholesterol 4458 - 9 in animals; see Mattson, Jandaoek and Glueck, Clinical Research 23 445A (1975). Similar results have been noted in humans.
In studies of the foregoing type, rats which ingested about 300 mg. to about 3000 mg. total liguid polyester per day and human volunteers who ingested from about 10 grams to about 50 grams total liguid polyester per day exhibited anal leakage of the polyesters . Further studies indicated that this anal leakage effect was a direct result of the passage cf the polyesters through the anal sphincter. Briefly, this undesired effect is not unlike the effect which can be caused by the ingestion of excessive amounts of mineral oil. It has now been determined that this undesirable effect can be obviated by combining the liquid polyester compositions with certain AAL agents.
The following is a brief description of animal studies whereby the effect of the ingestion of the nonabsorbable, non-digestible sucrose polyesters herein on vitamin A (an oil-soluble vitamin) uptake in rats was first determined.
In general terms, the animal studies involved feeding groups of rats a vitamin A-free diet for seven days. During this time, the animals were fed either cottonseed oil (CSO) or SPE, or mixtures of the two, as the sole source of fats in the diet. (The SPE is described in more detail hereinafter).
After the initial seven-day period, the diets of the animals were supplemented with vitamin A. Following the seven days on the diets containing vitamin A, the animals were sacrificed and their livers were removed and analyzed for vitamin A content by the CarrPrice method, using the procedure of Ames, Risley and Harris.
In studies of the foregoing type the marked - 10 differences of the response of the animals to the type of dietary fat ingested was unequivocal. Thus, when the dietary fat was CSO, over 70S of the vitamin A that was consumed was stored in the liver. The complete replacement of the normal dietary fats with SPE resulted in the storage of less than IOS of the vitamin A that was consumed.
In light of studies of the foregoing type, it is possible to provide a picture of the effect of SPE on fat-soluble vitamin (and cholesterol) uptake by the individual. Under usual dietary conditions (i.e., when ingesting ordinary absorbable, digestible oils or fats such as CSO), vitamin A, like cholesterol, initially is dissolved in an oil phase of triglycerides in the lumen of the intestinal tract. A portion of the triglycerides is hydrolyzed to monoglycerides and free fatty acids which, together with bile salts, form a micellar phase. Vitamin A is then distributed between the oil phase of unhydrolyzed triglyceride and the micellar phase. The proportion of vitamin A in each will be a function of the volume of each phase and the distribution coefficient of the vitamin. Eventually, almost all of the triglycerides are hydrolyzed and a major portion of the vitamin is absorbed.
In contrast, SPE and triglycerides are miscible. When both are present, a single oil phase is formed.
The digestion products of the triglycerides enter the micellar phase but SPE, because it is not hydrolyzed, remains as an oil phase. A significant portion of the ingested vitamin A (and cholesterol) remains in this SPE oil phase, the amount again depending on the volume coefficient of the vitamin. When the SPE is discharged, unchanged, in the stools, the oil-soluble viramin A dissolved in the SPE is also lost. A similar sequence of events presumably occurs also in the case of vitamin 4 4 5 8 - 11 E and also with the other fat-soluble vitamins, D and K.
As can be seen from the foregoing, the physicochemical properties which make the SPE so useful in preventing uptake of cholesterol by the body are the selfsame properties which undesirably interfere with uptake of fat-soluble vitamins.
This type of interference with the absorption of vitamins A and E has been demonstrated in human volunteers who consumed SPE. The consequence of SPE Ingestion was a drop in the blood (plasma) levels of these vitamins.
By the present invention SPE-type polyesters are fortified with fat-soluble vitamins, especially vitamin A, vitamin E and vitamin D, and mixtures thereof. (The polyesters can also be fortified with vitamin K. However, since the body can synthesize vitamin X, supplementation of the polyesters therewith is probably not critical to adequate nutrition in the normal subject). The vitaminfortified polyesters are used as fat substitutes in foods, in unit dose forms as pharmaceutical compositions, or are provided in bulk form for self-administration in a therapeutic or dietetic regimen.
The types of AAL agents which can be used herein to overcome the above-described anal leakage problem without interfering with the beneficial effects of the present compositions are disclosed immediately hereinafter.
Anti-Anal Leakage Agents One class of materials which provide the antianal leakage effect herein includes edible, digestible sources of saturated fatty acids having a melting point of ca, 37°C, or higher; the acids in question, are 2 and higher saturated fatty acids, for example, the C'2-C24 saturated fatty acids. 4 5 8 - 12 While not intending to be limited by theory, it appears that the foregoing type of AAL agent functions via the formation of calcium or magnesium fatty acid soaps in the gut. These soaps apparently interact with the liquid polyesters herein and impart a stiffening effect thereto. Once stiffened, or partly solidified, in the gut, the polyesters do not leak through the anal sphincter. The antihypercholesterolemic effect of the liquid polyesters is not diminished.
Non-limiting examples of sources of the saturated fatty acids which can be used as the AAL agent herein include compounds such as. esters (e.g., triglycerides) that yield such saturated fatty acids on hydrolysis in the gut, soaps of the fatty acids such as the sodium, potassium, etc., water-soluble soaps, as well as the calcium and magnesium water-insoluble soaps.
Highly preferred herein for their anti-anal leakage effect are sources of the Cig-C22' roost preferably C-jg-C-,θ, saturated fatty acids.
Specific examples of materials useful as the foregoing type of AAL agent herein include natural or processed fats yielding C]_2-C24' saturated fatty acids in the gut, e.g., materials such as cocoa butter, palm oil, palm kernel oil, coconut oil, tallow, lard, enriched concentrates of triglycerides having high levels of saturated fatty acids obtainable from these sources and sources such as highly saturated cottonseed oil fractions obtained by processes such as crystallization or directed rearrangement which yield the desired higher concentrations of the more saturated fatty acids in the resulting hardstook fractions. Such materials are all available by well-known processes.
Partially hydrogenated oils, including all of the above, as well as partially hydrogenated soybean oil, safflower seed oil, rapeseed oil, or such materials which are hydrogenated and concentrated, fc-r example by crystallization, to provide fractions which are enriched in sources of the longer-chain, substantially saturated fatty acids, are all useful as the AAL agent herein, (By substantially hydrogenated herein is meant oils having an iodine value of ca. 50, or lower.) Of course, any of the foregoing unsaturated oils are useful herein after they have been substantially completely hydrogenated to convert the unsaturated fatty acid (ester) groups to the corresponding saturated fatty acids.
Synthetic materials, especially fatty acid esters made from the C^2~C24' more preferably C^g-C22> most preferably cpgcpg, saturated fatty acids are useful herein. Such materials include the esters of tetrahydric alcohols such as erythritol, esters of pentahydric alcohols such as xylitol, and esters of hexahydric alcohols such as sorbitol, and the like.
The C^2-C2^ saturated fatty acid esters of ci-c6 alcohols, for example monohydric alcohols such as methyl, ethyl and propyl alcohols (preferably ethyl alcohol) are also useful herein. Esters of dihydric alcohols such as 1,2-propanediol, and 1,3-butanediol, can also be used.
Highly preferred AAL agents herein which yield the foregoing fatty acids on hydrolysis in the gut are those which, in combination with the liquid polyesters herein, provide compositions having aesthetically pleasing organoleptic qualities, i.e., better mouth feel. Such aesthetically pleasing materials include naturally occurring cocoa butter and various synthetic cocoa and confectioners' butters. These preferred AAL agents include, for example, the so-called positionspecific triglycerides such as 1-stearoyl diolein (S00); 2-oleoyl-l, 3-distearin (SOS); or the 4 4 5 8 corresponding compounds wherein the stearoyl group is replaced by palmitoyl, arachidoyl or behenoyl groups. Another class of aesthetically preferred anti-laxative agents herein are 1-oleoyl distearin (OSS), 1-palmitoyl distearin (PSS), 1-arachidoyl distearin (ASS) and 1-behenoyl distearin (BSS).
These highly preferred, position-specific triglycerides which can be used as a fatty acid sourcetype of AAL agent herein can be prepared according to the methods described in U.S. Patent 3,809,711, Yetter, issued May 7, 1974.
As noted hereinabove, the foregoing types of AAL agents appear to function by providing a saturated fatty acid in the gut, said fatty acid thereafter presumably forming an insoluble calcium or magnesium soap in situ. This soap then appears to provide the stiffening effect on the liquid polyester, thereby preventing the undesirable anal leakage effect. As noted hereinabove, the solid polyester materials of the present type (i.e., solid, edible, but nondigestible, non-absorbable polyesters) do not cause the undesirable anal leakage effect. It has been determined that these solid polyester materials can also be used as an AAL agent and these represent a second class of AAL agents herein. Since these solid polyester materials do not hydrolyze in the gut to form free fatty acids, or calcium or magnesium fatty acid soaps, their anti-anal leakage effect must be the result of a different mechanism from that which operates with the hydrolyzable esters and fatty acid sources described immediately hereinabove. Presumably, the combination of the solid polyester with the liquid polyesters simply provides a stiffening effect due to some type of crystallization or phase change within the gut.
It will be appreciated that by combining liquid 4 4 5 8 - 15 and solid non-absorbable, non-digestible polyesters to provide the desired anti-anal leakage effect, wholly edible, but non-digestible, non-absorbable, non-caloric compositions are secured. These compositions are quite effective in the treatment of hypercholesterolemia and in low calorie diets.
Typical examples of solid, non-absorbable, nondigestible polyester AAL agents herein include sucrose cctastearate, sucrose octapalmitate, sucrose heptastearate, xylitol pentastearate, galactose pentapalmitate, and like saturated polyol polyesters having at least four -OH groups esterified with saturatei^ fatty acids.
Another type of AAL agent herein comprises fatty acid esters which are ncn-digestible by virtue of branching on the σ-carbon atom of the fatty acid moiety. Such materials, which are well known in the chemical arts, include, for example, σ-methyi and a, «-dimethyl Cl0~Cl8 fatfcy esters of lower alcohols such as ethanol and of polyols such as glycerol.
Liquid Polyesters The liquid polyol polyesters (or, simply, polyesters) employed in this invention comprise certain polyols, especially sugars or sugar alcohols, esterified with at least four fatty acid groups. Accordingly, the polyol starting material must have at least four esterifiable hydroxyl groups. Examples of preferred polyols are sugars, including monosaccharides and disaccharides, and sugar alcohols. Examples of monosaccharides containing four hydroxyl groups are xylose and arabinose and the sugar alcohol derived from xylose, which has five hydoxyl groups, i.e., xylitol. (The monosaccharide, erythrose, is not suitable in the practice of this invention since it only contains three hydroxyl groups, but the sugar alcohol derived from erythrose, i.e. erythritol, contains four hydroxyl groups and 4 4 5 8 - 16 accordingly can be used). Suitable five hydroxyl groupcontaining monosaccharides are galatose, fructose, and sorbose. Sugar alcohols containing six-OH groups derived from the hydrolysis products of sucrose, as well as glucose and sorbose, e.g., sorbitol, are also suitable. Examples of disaccharide polyols which can be used include maltose, lactose, and sucrose, all of which contain eight hydroxyl groups.
Preferred polyols for preparing the . polyesters for use in the present invention are selected from the group consisting of erythritol, xylitol, sorbitol, glucose and sucrose. Sucrose is especially preferred.
The polyol starting material having at least four hydroxyl groups must be esterified on at least four of the -OH groups with a fatty acid containing from about 8 to about 22 carbon atoms. Examples of such fatty acids include caprylic, capric, lauric, myristic, myristoleic, palmitic, palmitoleric, stearic, oleic, ricinoleic, linoleic, linolenic, eleostearic, arachldic, arachidonic, behenie, and erucic acid. The fatty acids can be derived from naturally occurring or synthetic fatty acids; they can be saturated or unsaturated, including positional and geometrical isomers. However, in order to provide liquid polyesters of the type used herein, at least about half, of the fatty acid incorporated into the polyester molecule must be unsaturated.
Oleic and linoleic acids, and mixtures thereof, are especially preferred.
The liquid polyol fatty acid polyesters useful in this invention must contain at least four fatty acid ester groups. Polyol fatty acid polyester compounds that contain three or less fatty aoid ester groups are digested in and the products of digestion are absorbed from the intestinal tract much in the manner of ordinary triglyceride fats, whereas the polyol fatty acid 4 4 5 8 - 17 polyester compounds that contain four or more fatty acid ester groups are substantially non-digestible and consequently non-absorbable by the human body.
It is not necessary that all of the hydroxyl groups of the polyol be esterified with fatty acid, but it is preferable that the polyester contain no more than two unesterified hydroxyl groups. Most preferably, substantially all of the hydroxyl groups of the polyol are esterified with fatty acid, i.e., the compound is substantially completely esterified. The fatty acids esterified to the polyol molecule can be the same or mixed (but, as noted above, a substantial amount of the unsaturated acid ester groups must be present to provide liquidity).
To illustrate the above points, a sucrose fatty triester would not be suitable for use herein because it does not contain the required four fatty acid ester groups. A sucrose tetra-fatty acid ester would be suitable, but is not preferred because it has more than two unesterified hydroxyl groups. A sucrose hexa-fatty acid ester would be preferred because it has no more than two unesterified hydroxyl groups. Highly preferred compounds in which all the hydroxyl groups are esterified with fatty acid include the liquid sucrose octa-fatty acid esters.
The following are non-limiting examples of specific liquid polyol fatty acid polyesters containing at least four fatty acid ester groups suitable for use in the present inventions glucose tetraoleate, the glucose tetraesters of soybean oil fatty acids (unsaturated) , the mannose tetraesters of mixed soybean oil fatty acids, the galactose tetraesters of oleic acid, the arabinose tetraesters of linoleic acid, xylose tetralinoleate, galactose pentaoleate, sorbitol tetraoleate, the sorbitol hexaesters of unsaturated soybean oil fatty acids, xylitol pentaoleate, sucrose tetraoleate, 4.4 S 8 - 18 sucrose pentaoleate, sucrose hexaoleate, sucrose heptaoleate, sucrose octaoleate, and mixtures thereof.
As noted above, highly preferred polyol fatty acid esters are those wherein the fatty acids contain from about 14 to about 18 carbon atoms.
The polyol fatty acid polyesters suitable for use herein can be prepared by a variety of methods well known to those skilled in the art. These methods include: transesterification of the polyol with methyl, ethyl or glycerol fatty acid esters using a variety of catalysts; acylation of the polyol with a fatty acid chloride; acylation of the polyol with a fatty acid anhydride? and acylation of the polyol with a fatty acid, per se. As an example, the preparation of polyol fatty acid esters is described in U.S. Patent 2,831,854.
Specific, but non-limiting, examples of the preparation of polyol fatty acid esters suitable for use in the practice of this invention are as follows.
Erythritol tetraoleate - Erythritol and a five20 fold molar excess of methyl oleate are heated at 180°C, under vacuum, with agitation, in the presence of sodium methoxide catalyst over two reaction periods of several hours each. The reaction product (predominantly erythritol tetraoleate) is refined in petroleum ether and crystallized three times from several volumes of acetone at 1°C.
Xylitol pentaoleate - Xylitol and five-fold molar excess of methyl oleate in diamethylacetamide (DMAC) solution are heated at 180°C for five hours in the presence of sodium methoxide catalyst, under vacuum. During this time the DMAC is removed by distillation.
The product (predominantly xylitol pentaoleate) is refined in petroleum ether solution and, after being freed of petroleum ether, is separated as a liquid layer four times from acetone at ca. 1°C and twice from alcohol - 19 at ca. 10°C.
Sorbitol hexaoleate is prepared by essentially the same procedure used to prepare xylitol pentaoleate except that sorbitol is substituted for xylitol.
Sucrose octaoleate is prepared by substantially the same procedure as that used to prepare erythritol tetraoleate except that sucrose is substituted for erythritol.
Vitamins The vitamins used to fortify the foregoing polyesters in the preferred execution of the invention herein are described in detail hereinafter. It will be appreciated that commercial preparations of the appropriate vitamins and/or appropriate vitamin mixtures which provide vitamins A, D, E and K can be used herein.
In general terms, the vitamins are classified as either fat-soluble or water-soluble. The fatsoluble vitamins are used to fortify the polyester materials herein. The fat-soluble vitamins include vitamin A, vitamin D, vitamin E, and vitamin K.
Vitamin A (retinol) can be used to fortify the polyesters herein. Vitamin A is a fat-soluble alcohol of the formula H2g OH. Natural vitamin A is usually found esterified with a fatty acid; metabolically active forms of vitamin A also include the corresponding aldehyde and acid. All such fat-soluble forms of vitamin A (including the carotenoids) are contemplated for use in the present invention and are considered to be encompassed by the term vitamin A as used herein. The role of vitamin A in normal human metabolism has not been established with certainty, but it is known that this vitamin is essential to proper vision.
Vitamin D (calciferol) can be used to fortify the polyesters herein. Vitamin D is a fat-soluble vitamin •ΐ 4 4 5 8 - 20 well known for use in the treatment and prevention of rickets and other skeletal disorders. Vitamin D comprises sterols, and there are at least 11 sterols with vitamin D-type activity. Of these, only those known as and Dg are of substantial practical importance. Ergosterol, a plant sterol closely related to cholesterol in structure, is known as provitamin D2 and 7-dehydrQcholesterol is known as provitamin Og. Each of these provitamins is converted to the corresponding active form by irradiation with ultra-violet light. Ergocalciferol (D2) is prepared commercially for use as a vitamin supplement. Cholecalciferol (Dg) is a form synthesized in animal tissues and is chiefly found in the natural fish oils. The present invention fully contemplates the use of any of the vitamins and provisions having vitamin D-type activity and the term vitamin D” as used herein is intended to encompass all such fat-soluble materials.
Vitamin E (tocopherol) is a third fat-soluble vitamin which can be used in the present invention. Four different tocopherols have been identified (alpha, beta, gamma and delta), all of which are oily, yellow liquids, insoluble in water but soluble in fats and oils. Of the four tocopherols, alpha is the most active biologically, a factor which may be related to better absorption from the intestine. Delta tocopherol is the most potent antioxidant of the four. It has been suggested that-vitamin E deficiency may cause a variety of symptoms such as fetal abnormalities and deaths, myocardial degeneration, and necrosis of the liver, but the role of this vitamin in human nutrition is not yet well established. The term vitamin Ξ as employed herein is intended to encompass all the fat-soluble tocopherols having vitamin E-type activity.
Vitamin K exists in at least three forms, all belonging to the group of chemical compounds known as 4 4 5 S - 21 quinones. The naturally-occurring fat-soluble vitamins are Kj (phylloquinone), K2 (menaquinone) and K^ (menadione). Vitamin K deficiency usually results in poor clotting of the blood, among other symptoms. The term vitamin K as employed herein is intended to include all the foregoing fat-soluble quinones having vitamin K-type activity.
From the foregoing it is to be understood that vitamins A, D, E and K, the corresponding provitamins and derivations thereof, such as esters, having vitamin A, Ij, E or K-type activity in animals, especially humans, are fully contemplated for use herein and are encompassed by the term vitamin as used herein.
The amount of the individual fat-soluble vitamins used to fortify the present compositions can vary with the age of the recipient, the dosage regimen used, and the amount of the vitamin ingested from other dietary sources. For example, in younger, growing children or in pregnant females it is recognized that larger amounts of any given vitamin should be ingested to supply optimal nutritional benefits than are needed with adult males. If the user of the present compositions happens to ingest foods which are extremely rich in a given fatsoluble vitamin, less of that vitamin need be used in the present compositions to insure adequate intestinal uptake for good nutrition. In any event, an attending physician can, if so desired, measure the amount of fatsoluble vitamins in the plasma. Based on these data, the appropriate type and amount of fat-soluble vitamin used to fortify the polyesters herein can then be determined on an individual basis.
More simply, the formulator of the compositions herein can fortify the polyesters with a recommended daily allowance (RDA), or increment or multiple of an RDA, of any of the fat-soluble vitamins to insure 4 4 5 8 - 22 that the user of the compositions will maintain a nutritionally adequate uptake of said vitamins. For example, with vitamin A a daily amount in the range of 20 international units (I.U.) to about 57 I.U. per kilogram of body weight can be employed. With vitamin D, fortification of the compositions to provide about 400 I.U., total, per day is ample. When supplementing with vitamin E, the amount of the vitamin optimal for dietary intake ranges from 3-6 I.U. for infants to 25-30 I.U., total, per day, for adults. When supplementing with vitamin K, it is more difficult to estimate the amount to be ingested to provide adequate nutrition since the microorganisms living in the intestine can synthesize this vitamin. However, it is known that ingestion of from 0.5 mg.-l mg. of vitamin K per day will prevent insufficiency.
As can be seen from the foregoing, the amount of the fat-soluble vitamins employed herein to fortify the polyesters can vary. In general, the polyesters are fortified with sufficient fat-soluble vitamin to provide from about 0.08% to about 150% of the average RDA. A preferred composition of the invention comprises from 50% to 90% by weight of the liquid polyol fatty acid polyester, at least 9.999% by weight of the anti-anal leakage agent, and from 0.001% to 2% by weight of the vitamin.
In therapeutic regimens the dosage of the compositions herein can vary with the severity of the hypercholesterolemia condition and the duration of the treatment. Individual dosages can range from about 0.01 mg/kg. to about 500 mg/kg., and greater (unless otherwise specified, the unit designated mg./kg. as used herein refers to mg. of liquid polyester per kilogram, of body weight), preferably from about 0.1 mg./kg. to about 125 mg./kg. per dosage, with up to six dosages, preferably three dosages, being given daily, most prefer4 4 4 5 8 ably at meal times. Because of the AAL agent, such high dosages can be administered without fear of producing anal leakage effects. Dosages of less than about 0.1 mg./kg. do not materially inhibit the absorption of cholesterol in most patients. The dosages can be administered orally in any suitable unit dosage form such as pills, tablets, and capsules. Preferred are capsules made from gelatin. The dosages can also be administered as part of a controlled dietary regimen, e.g., as a synthetic salad oil or cooking oil or fat.
The pharmaceutical compositions herein can comprise the polyester/AAL agent with or without fortifying fat-soluble vitamins alone, or in combination with any desired, non-interfering pharmaceutical carrier. As used herein, the term pharmaceutical carrier means a solid or liquid filler, diluent or encapsulating substance. Some examples of the substances which can serve as pharmaceutical carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium earboxymethylcellulose, ethyloellulose, cellulose acetate; powdered tragacanth; malt; gelatin; talc; oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and soybean oil; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; agar; alginic acid; pyrogen-free water; isotonic saline; ethyl alcohol and phosphate buffer solutions, as well as other non-toxic compatible substances used in pharmaceutical formulations. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents and preservatives can also be present in the compositions, according to the desires of the formulator.
The pharmaceutical carriers of the foregoing type can optionally be employed in conjunction with the liquid polyesters herein to provide a practical size to 4 4 5 8 - 24 dosage relationship, composition forms which can be easily ingested, and means for providing accurate unit dosages in a convenient form. The pharmaceutical carrier usually will comprise from about 5% to about 50% by weight of the total pharmaceutical composition.
Since the liquid polyesters of the present compositions are not unlike cooking and salad oils and fats in their physical properties, the present compositions can be used as a partial or total replacement for normal triglyceride fats in any fat-containing food composition to provide anti-hypercholesterolemic and low calorie benefits. In order to achieve these benefits in a reasonable time, it is necessary that at least about 10¾ of the fat in the food composition comprises the polyesters herein. Highly desirable food compositions are those wherein the fatty component comprises up to about 100S of the polyester/anti-anal leakage compositions herein. Accordingly, the compositions of this invention can be used as a partial or complete replacement for normal triglyceride fats in a salad or cooking oil, or in plastic shortenings for use in frying, cake making, bread making, and the like. The compositions can also be used as partial or complete replacements for normal triglyceride fats in fat-containing food products such as mayonaise, margarine, and dairy products.
Preferred fat-containing food compositions of the present type comprise non-fat ingredients and fat ingredients wherein from 10% to 100%, preferably from 10% to 95% of the total fat consists essentially of a liquid sugar fatty acid polyester having at least four fatty acid ester groups, each fatty acid having from about 8 to about 22 carbon atoms, said sugar fatty acid polyester and/or food composition made therefrom also comprising an AAL agent of the type disclosed herein and, preferably, being fortified with the fat-soluble vitamins. Such food compositions will most often contain at least 4 4 5 8 - 25 about 10%, generally 15% to 25% (by weight of liquid polyester) of a fatty acid source which provides the anti-anal leakage effect. Highly preferred are food compositions wherein the sugar fatty acid ester contains no more than two unesterified hydroxy groups. Liquid sucrose polyesters, especially those wherein the ester groups are mainly of the unsaturated type and contain 14 to 18 carbon atoms, when used in the manner of this invention, are especially preferred for use in such anti-hypercholesterolemic and low calorie food compositions.
The total AAL agent employed in any of the compositions and methods herein will depend somewhat on the total amount of liquid polyester being ingested per day. The anti-anal leakage agent should preferably be present in an amount equaling at least about 10% by weight of the liquid polyester. It is more preferred that the AAL agent comprises at least about 20% by weight of the liquid polyester to ensure that anal leakage does not occur, even at high ingestion rates. Compositions wherein the weight of AAL agent comprises from about 20% to about 50% of the weight of liquid polyester provide excellent control of serum cholesterol without anal leakage of the polyester.
Compositions comprising edible fatty acids, their edible salts or their edible, digestible esters wherein the weight of AAL agent comprises about 10% to about 50% by weight of these materials by weight of liquid polyester. Compositions using the palatable position-specific triglycerides as the AAL agent preferably comprise about 20% to about 40% (by weight of liquid polyester) of these AAL agents. When the edible, non-absorbable non-digestible solid polyesters are used as the AAL agent, they are preferably used at a rate of from about 20% to about 50% by weight of the liquid polyester.
The following, non-limiting examples illustrate the compositions and processes of this invention. It will 4 5 8 - 26 be appreciated that sugars and sugar alcohols, appropriately esterified, are encompassed by the term sugar as used herein and such materials can be inter-changed in the compositions.
EXAMPLE X.
Gelatin capsules for use by the hypercholesterolemic patient are prepared by conventional methods, as follows : Ingredient Amount per Capsule Sucrose polyester* 2000 mg.
Methyl Stearate 250 mg.
*Liquid, mixed hexa-, hepta- and oeta-sucrose esters, predominantly the octa-ester, esterified with mixed soybean oil fatty acids, predominantly in the C^g-Ο^θ chain length.
The capsules of the foregoing type are prepared by simply mixing the ingredients and filling the standard gelatin capsules. The capsules are administered orally three times daily (three times each meal). This treatment regimen inhibits cholesterol uptake significantly and decreases the serum cholesterol levels in the circulatory systems of humans with, or disposed towards, hypercholesterolemia. The patients are not troubled by undesired anal leakage with this regimen.
Similar results are obtained when the sucrose polyester in the capsules of Example I is replaced with an equivalent quantity of a fatty acid polyester selected from the group consisting Of glucose tetraoleate; glucose tetrastearate mixed glucose tetraesters of unsaturated soybean oil fatty acids; mixed mannose tetraesters of oleic acid; mixed galactose tetraesters of linoleic acid; mixed arabinose tetraesters of oleic aeid; ι ι ft - 27 xylose tetralinoleate; galactose pentaoleate; sorbitol tetraoleate; sucrose tetraoleate; sucrose pentaoleate; sucrose hexaoleate; sucrose heptaoleate; and sucrose octaoleate, respectively.
In the composition of Example I, the methyl stearate anti-anal leakage ingredient is replaced by an equivalent amount of propyl stearate, methyl behenate, ethyl behenate, substantially completely hydrogenated palm oil, hydrogenated rapeseed oil, and mixed hydrogenated tallow triglycerides, respectively, and equivalent results are secured.
Preferred pharmaceutical compositions of the type of Example I for inhibiting the absorption of cholesterol, especially in the human body, preferably comprise from about 0.1 gram to about 5 grams of the liquid polyester and an effective amount (as disclosed hereinabove) of the ZiAL agent.
EXAMPLE II.
Gelatin capsules for use by the hypercholesterolemic patient are prepared by conventional methods, as follows: Ingredient Amount per Capsule Sucrose polyester* Retinol Methyl stearate 2000 mg. 0.3 RDA 750 mg.
*Liquid, mixed hexa-, hepta- and octa-sucrose esters, predominantly the octa-ester, esterified with mixed soybean oil fatty acids, predominantly in the c^gc]g chain length.
The capsules of the foregoing type are prepared by simply mixing the ingredients and filling the standard gelatin capsules. The capsules are administered orally 4 5 8 - 28 three times daily (three with each meal). This treatment regimen inhibits cholesterol uptake significantly and decreases the serum cholesterol levels in the circulatory systems of humans with, or disposed towards, hypercholesterolemia. Vitamin A levels in the patients are not decreased significantly from the normal. The patients are not troubled by undesired anal leakage with this regimen.
Similar results are obtained when the sucrose polyester in the capsules of Example II is replaced with an equivalent quantity of a fatty acid polyester selected from the group consisting of glucose tetraoleate? glucose tetrastearate; mixed glucose tetraesters of soybean oil fatty acids; mixed mannose tetraesters of tallow fatty acids; mixed galactose tetraesters of olive oil fatty acids; mixed arabinose tetraesters of cottonseed oil fatty acids? xylose tetra linoleate; galactose pentastearate? sorbitol tetraoleate? sucrose tetrastearate; sucrose penta20 stearate; sucrose hexaoleate? sucrose heptaoleate? and sucrose octaoleate respectively.
In the composition of Example II the retinol is replaced by an equivalent dosage level of a commercial vitamin A ester concentrate and equivalent results are secured.
In the composition of Example II, the methyl stearate anti-anal leakage ingredient is replaced by an equivalent amount of ethyl stearate, propyl stearate, methyl behenate, ethyl behenate, hydrogenated palm oil, hydrogenated rapeseed oil and mixed hydrogenated tallow triglycerides, respectively, and equivalent results are secured.
Preferred compositions of the type of Example II for inhibiting the absorption of cholesterol, especially in the human body, preferably comprise from about 0.1 gram to about 5 grams of the liquid polyester, 4 4 5 8 - 29 an effective amount (as disclosed hereinabove) of the AAL agent and at least about 0.1 RDA of one or more of the fat-soluble vitamins.
EXAMPLE III.
Gelatin capsules comprising a unit dose of an AAL agent and a liquid polyester are prepared by conventional means, as follows: Ingredient Amount per Capsule Sucrose octaoleate 3500 mg.
Hydrogenated palm oil 750 mg.
The above capsules are administered orally three times daily (three per meal/70 kg. man) over a one-month period. This treatment regimen substantially inhibits cholesterol uptake in the patient and decreases the serum level of cholesterol. No anal leakage from use of the capsules is noted.
The hydrogenated palm oil in Example III is replaced by an equivalent amount of tristearin and equivalent anti-anal leakage results are secured.
When oleic acid is used to replace the hydrogenated palm oil, no substantial anti-anal leakage effect is noted.
The above capsules are fortified with vitamin E which consists of mixed alpha, beta, gamma and delta tocopherols using 0.2 RDA of vitamin E per capsule.
The capsules are additionally fortified with sufficient β-carotene to provide a 0.25 RDA of vitamin A per capsule.
EXAMPLE IV.
Gelatin capsules comprising an AAL agent and a - 30 4 4458 liquid polyester are as follows; Ingredient Mg. per Capsule Sucrose octaoleate 2000 Ethyl stearate 250 Three capsules of the type prepared in Example IV are administered orally five times daily (three capsules per occurrence) to inhibit cholesterol uptake and decrease the level of cholesterol in the circulatory system Of a 70 kg. patient afflicted with hypercholesterolemia. At these dosage levels, no anal leakage is noted. Similar dosages of the foregoing capsules without ethyl stearate cause an undesired leakage of sucrose octaoleate through the anal sphincter.
EXAMPLE V.
Gelatin capsules comprising an AAL agent, a liquid polyester and containing a mixture of the fatsoluble vitamins are as follows: Ingredient Mg. per Capsule Sucrose ootaoleate 20 Vitamin A Vitamin D Vitamin E Vitamin K Ethyl stearate 2000 0.1 0.01 0.1 0.1 750 The vitamin A employed in the capsules of Example V is retinol; the vitamin D is a 1:1 mixture of irradiated ergosterol and irradiated 7-dehydrooholesterol; the vitamin E comprises a commercial mixture of alpha, beta, gamma and delta tocopherols; and the vitamin K comprises the fat-soluble phyllo4 4 4 5 8 - 31 qurnone.
Three capsules of the type prepared in Example V are administered orally five times daily (three with each meal) to inhibit cholesterol uptake and decrease the level of cholesterol in the circulatory system of a 70 kg. patient afflicted with hypercholesterolemia.
The body levels of fat-soluble vitamins A, D, E and K do not decrease below normal. No anal leakage is noted. Similar capsules in this dosage range without ethyl stearate cause an undesired laxative effect, i.e., leakage of polyester through the anal sphincter.
EXAMPLE VI.
A highly palatable, low calorie composition suitable for use by patients on anti-hypercholesterolemic therapeutic regimens and/or as a cooking fat substitute by individuals on an anti-hyperlipidemic diet is as follows: Ingredient Liquid sucrose polyester* Cocoa butter % by Weight *Avg. 7.5 ester of sucrose and oleic acid.
The composition of the foregoing type is suitable for use in standard fashion as a low calorie cooking fat. No anal leakage of the liquid polyester is noted.
The composition of Example VI is ingested at a rate of 50 g./day (150 lb. patient) and reduces serum cholesterol without anal leakage of the liquid polyester In the composition of Example VI the natural cocoa butter is replaced by an equivalent amount of the position-specific triglycerides SOO, SOS, OSS, PSS, ASS Λ 4 4 5 8 - 32 and BSS, respectively, and equivalent compositions are secured.
In the compositions of Example VI the liquid sucrose polyester comprising average 7.5 ester of sucrose and unsaturated, mixed soybean oil fatty acids fortified to provide 1000 I.U. of vitamin A per ounce of composition. Equivalent results are obtained and no depletion of Vitamin A in the tissues is caused.
EXAMPLE VII.
A plastic shortening is prepared from the following ingredients.
Ingredient Cocoa butter Liquid xylitol pentaoleate OSS % by Weight The composition of Example VII is prepared by thoroughly mixing the indicated ingredients. The composition is suitable for use in frying and other types of cooking where a plastic fat is employed. The fat composition of Example VII can also be employed in the preparation of baking doughs suitable for use by the hypercholesterol patient. Continued ingestion of the plastic shortening of Example VII, or foods made therefrom, reduces the body's serum cholesterol level Without anal leakage of the xylitol pentaoleate.
The shortening of Example VII can be used by the normal or hyperlipidemic patient to control body weight.
The composition of Example VII is fortified with sufficient irradiated ergosterol to provide 40.0 I.U. of vitamin D per two ounce serving. Equivalent 4 4 5 8 - 33 results are obtained and vitamin D deficiency does not result.
EXAMPLE VIII, A non-anal leakage, low calorie, antihypercholesterolemic composition prepared with an edible, but non-absorbable, non-digestable, solid polyester AAL agent is as follows; Ingredient % by Weight Sucrose octaoleate 70 Sucrose octastearate 30 The composition of Example VIII is prepared by simply combining the ingredients. The composition is suitable for use by the hypercholesterolemic patient to reduce serum cholesterol levels; no anal leakage is noted.
The composition of Example VIII can be used by the normal or hyperlipidemic patient to control serum cholesterol without increasing calorie intake.
In the composition of Example VIII the sucrose octastearate is replaced by an equivalent amount of sucrose heptastearate, and sucrose octapalmitate, respectively, as the AAL agent and equivalent results are secured.
The composition of Example VIII is vitaminfortified with a commercial mixture of vitamins A, D, E and K sufficient to provide an RDA of each of these vitamins per three ounce serving.
Equivalent results are obtained while maintaining normal levels of the fat-soluble vitamins.

Claims (22)

1. An anti-hypercholesterolemia and/or antihyperlipidemia composition, comprising: (a) an edible non-absorbable, non-digestible polyol fatty acid polyester which is liquid (as hereinbefore defined) and which has at least 4 fatty acid ester groups, wherein the polyol is selected from the group consisting of sugars and sugar alcohols containing from 4 to 8 hydroxyl groups and wherein each fatty acid group has from about 8 to about 22 carbon atoms; and (b) sufficient anti-anal leakage agent to prevent leakage of said liquid polyester through the anal sphincter, the anti-anal leakage agent being selected from edible, digestible sources of C^ 2 and higher saturated fatty acids (other than the acids per se); edible, non-absorbable, non-digestible solid polyol fatty acid polyesters having at least 4 fatty acid ester groups, wherein the polyol is selected from the group consisting of sugars and sugar alcohols containing from 4 to 8 hydroxyl groups and wherein each fatty acid group has from about 8 to about 22 carbon atoms; and edible, non-digestible esters of alpha-branched chain C 1O -C 18 fatty acids, and mixtures thereof.
2. A composition according to claim 1 wherein the liquid polyol fatty acid polyester contains no more than about 2 free hydroxyl groups.
3. A composition according to claim 1 or claim 2 wherein the fatty acid ester groups of the liquid polyol polyester contain from about 14 to about 18 carbon atoms.
4. A composition according to any one of claims 1-3 wherein the polyol of the liquid polyol polyester is ί Ο Β 8 - 35 erythritol, xylitol, sorbitol, glucose or sucrose.
5. A composition according to claim 4 wherein the polyester is selected from the hexaoleate, heptaoleate and octaoleate of sucrose, and mixtures thereof.
6. A composition according to any one of claims 1-5 which comprises at least 10% of the antianal leakage agent, by weight of the liquid polyester.
7. A composition according to claim 6 which comprises from 20% to 50% of the anti-anal leakage agent, by weight of the liquid polyester.
8. A composition according to any one of claims 1-7 wherein the anti-anal leakage agent is selected from edible digestible sources of C^ 2 “ C 24 satu rated fatty acids.
9. A composition according to claim 8 wherein the anti-anal leakage agent is one or more C^-Cg alkyl esters of c i2~ C 24 satura ted fatty acids.
10. A composition according to claim 8 wherein the anti-anal leakage agent comprises one or more substantially saturated triglyceride esters of c y2~ C 24 fatty acids.
11. A composition according to claim 10 wherein the anti-anal leakage agent is hydrogenated palm oil.
12. A composition according to claim 10 wherein the anti-anal leakage agent is natural or synthetic cocoa butter.
13. A composition according to claim 10 wherein the anti-anal leakage agent is an edible position4 4 5 8 - 36 specific triglyceride selected from the group consisting of: the I-stearoyl, 1-palmitoyl, 1-arachidoyl and 1-behenoyl 2,3-dioleins; the 2-oleoyl 1,3-distearins, 1,3-dipalmitins, 1,3-diarachidins and 1,3-dibehenins; 1-oleoyl distearin; 1-palmitoyl distearin; 1-arachidoyl distearin; and 1-behenoyl distearin, and mixtures thereof.
14. A composition according to claims 1-7 wherein the anti-anal leakage saturated fatty acid polyol ester. any one of agent is C 1O “ C 22
15. A composition according to any one of claims 1-14 and additionally comprising sufficient fatsoluble vitamin selected from the group consisting of vitamin A, vitamin D, vitamin E, vitamin K and mixtures thereof to prevent abnormally lox·? levels of any of said fat-soluble vitamins in animals ingesting said composition.
16. A composition according to claim 15 which comprises from 50% to 90% by weight of the liquid polyol fatty acid polyester, at least 9,999% by weight of the anti-anal leakage agent, and from 0.001% to 2% by weight of the vitamin.
17. A lox·? calorie fat-containing food composition comprising non-fat ingredients and fat ingredients, wherein from 10% to 100% of the total fat ingredients is a composition according to any one of claims 1 to 16.
18. A pharmaceutical composition in effective unit dosage amounts for inhibiting the absorption of cholesterol without causing an anal leakage effect, comprising a composition as claimed in any one of claims 1-14 and in which the liquid polyol fatty acid polyester is present in an amount of from 0.1 gram to 5 grams. 4 4 4 5 8 - 37
19. A composition according to claim 18 which additionally comprises sufficient fat-soluble vitamin selected from the group consisting of vitamin A, vitamin D, vitamin E and vitamin K to prevent 5 abnormally low levels of any of said fat-soluble vitamins in animals ingesting said composition,
20. A composition according to claim 19 which contains at least about 0.1 RDA of vitamin.
21. A composition according to claim 1 10 substantially as hereinbefore described with reference to any one of the examples.
22. A method for inhibiting the absorption of cholesterol in non-human animals without causing an anal leakage effect comprising administering to a non15 human animal susceptible to or afflicted with hypercholesterolemia successive therapeutically effective doses of a composition as claimed in any one of claims 18-20.
IE213/77A 1976-02-12 1977-02-02 Compositions for treating hypercholesterolemia IE44458B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/657,528 US4005195A (en) 1976-02-12 1976-02-12 Compositions for treating hypercholesterolemia
US05/657,529 US4005196A (en) 1976-02-12 1976-02-12 Vitaminized compositions for treating hypercholesterolemia

Publications (2)

Publication Number Publication Date
IE44458L IE44458L (en) 1977-08-12
IE44458B1 true IE44458B1 (en) 1981-12-02

Family

ID=27097425

Family Applications (1)

Application Number Title Priority Date Filing Date
IE213/77A IE44458B1 (en) 1976-02-12 1977-02-02 Compositions for treating hypercholesterolemia

Country Status (8)

Country Link
JP (1) JPS52120131A (en)
DE (1) DE2705105A1 (en)
FR (1) FR2340737A1 (en)
GB (1) GB1579241A (en)
IE (1) IE44458B1 (en)
IT (1) IT1075126B (en)
LU (1) LU76751A1 (en)
NL (1) NL188503C (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4368213A (en) * 1981-06-23 1983-01-11 The Procter & Gamble Company Emulsion concentrate for palatable polyester beverage
EP0233856B1 (en) * 1986-02-20 1994-01-05 The Procter & Gamble Company Better tasting low calorie fat materials
DE3788443T2 (en) * 1986-02-20 1994-04-28 Procter & Gamble Low-calorie fat products that rule out the laxative side effects.
US4849222A (en) * 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JPH07108184B2 (en) * 1987-11-25 1995-11-22 三菱化学株式会社 Manufacturing method of chicorylate
US5006360B1 (en) * 1988-06-27 1992-04-28 Low calorie fat substitute compositions resistant to laxative side effect
CA2004723C (en) * 1988-12-22 1997-03-04 James Anthony Letton Fatty compositions with high solids content

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2997492A (en) * 1959-02-17 1961-08-22 Procter & Gamble Method for preparing fatty esters of straight chain hexitols
US2997491A (en) * 1959-09-29 1961-08-22 Procter & Gamble Method for preparing partial fatty esters of inositol
US3059009A (en) * 1961-09-21 1962-10-16 Proeter & Gamble Company Fat crystallization process
US3158490A (en) * 1962-03-27 1964-11-24 Procter & Gamble Salad oils and method of making them
US3600186A (en) * 1968-04-23 1971-08-17 Procter & Gamble Low calorie fat-containing food compositions
US3809711A (en) * 1972-04-07 1974-05-07 Procter & Gamble Process for synthesizing specific complete mixed polyol esters
US3954976A (en) * 1973-12-14 1976-05-04 The Procter & Gamble Company Pharmaceutical compositions for inhibiting absorption of cholesterol
US3963699A (en) * 1974-01-10 1976-06-15 The Procter & Gamble Company Synthesis of higher polyol fatty acid polyesters
US4034083A (en) * 1975-11-03 1977-07-05 The Procter & Gamble Company Compositions for inhibiting absorption of cholesterol
EP0236288B1 (en) * 1986-02-20 1993-12-15 The Procter & Gamble Company Low calorie fat materials that eliminate laxative side effect

Also Published As

Publication number Publication date
IE44458L (en) 1977-08-12
NL188503C (en) 1995-05-16
IT1075126B (en) 1985-04-22
DE2705105C2 (en) 1987-06-11
JPS52120131A (en) 1977-10-08
GB1579241A (en) 1980-11-19
LU76751A1 (en) 1977-08-19
FR2340737A1 (en) 1977-09-09
NL188503B (en) 1992-02-17
FR2340737B1 (en) 1981-01-09
JPS6339568B2 (en) 1988-08-05
DE2705105A1 (en) 1977-08-18
NL7701460A (en) 1977-08-16

Similar Documents

Publication Publication Date Title
USRE34617E (en) Vitaminized compositions for treating hypercholesterolemia
US4034083A (en) Compositions for inhibiting absorption of cholesterol
US4005195A (en) Compositions for treating hypercholesterolemia
US4241054A (en) Detoxifying lipophilic toxins
US4849222A (en) Mixtures for treating hypercholesterolemia
US4264583A (en) Gallstone dissolution compositions and method
US4950140A (en) Cookies containing psyllium
JP2003517051A (en) Low calorie fat composition
CA1340804C (en) Mixed compositions for treating hypercholesterolemia
Kritchevsky Impact of red palm oil on human nutrition and health
US5116610A (en) Compositions for treating hypercholesterolemia
USRE33885E (en) Compositions for inhibiting absorption of cholesterol
USRE33996E (en) Compositions for treating hypercholesterolemia
US4962092A (en) Compositions for treating duodenal ulcers
IE44458B1 (en) Compositions for treating hypercholesterolemia
US6821545B2 (en) Low calorie fat materials that eliminate laxative side effect
EP0415464A2 (en) Edible fat-containing products containing carotenoids
WO1992010941A1 (en) Edible fat-containing products containing vitamin e
US5910317A (en) Mixed compositions for treating hypercholesterolemia
Akoh Fat-based fat substitutes
WO2002049457A1 (en) The use of a non-absorbable, non-digestible lipid for the treatment of hyperbilirubinemia
IE60716B1 (en) Low calorie fat materials that eliminate laxative side effect

Legal Events

Date Code Title Description
MM4A Patent lapsed